HLA Markers for Poor Prognosis in Systemic Sclerosis Brazilian Patients

Imagem de Miniatura
Arquivos
art_SAMPAIO-BARROS_HLA_Markers_for_Poor_Prognosis_in_Systemic_Sclerosis_2013.PDF (1.31 MB)
Citações na Scopus
9
Tipo de produção
article
Data de publicação
2013
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
HINDAWI PUBLISHING CORPORATION
Autores
RIO, Ana Paula Toledo Del
SACHETTO, Zoraida
MARQUES-NETO, Joao Francisco
LONDE, Ana Carolina Santos
BERTOLO, Manoel Barros
Citação
DISEASE MARKERS, p.73-78, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objectives. The aim of this study was to evaluate human leukocyte antigen (HLA) involvement in the disease expression and poor prognostic clinical features (pulmonary fibrosis and pulmonary arterial hypertension) in patients diagnosed with systemic sclerosis (SSc) in a multiethnic population. Methods. SSc patients followed up between 2008 and 2011 were included, and clinical data were obtained through records review. Molecular HLA typing was performed (polymerase chain reaction amplification technique using specific primer sequences). The statistical analysis involved Fisher's exact test and Pearson's corrected chi-square test. P values < 0.05 were considered significant. The delta method was used to estimate the variance of the prevalence ratio (PR). Results. A total of 141 patients (120 women and 21 men) with SSc were studied, including 33.3% with diffuse cutaneous SSc (dcSSc), 62.4% with limited cutaneous SSc (lcSSc), and 4.3% with sine scleroderma. Pulmonary fibrosis was present in 61 patients (43.3%), and the HLA-A*30 and DQB1*04 alleles were related to susceptibility. In contrast, the HLA-DRB1*01 and DQB1*05 alleles were protective. Pulmonary arterial hypertension was diagnosed in 19 patients (13.5%) and was associated with HLA-B*35 and C*04; in contrast, C*03 seemed to be protective. Conclusions. Our current study documents the association of some classes I and II HLA alleles with the most severe clinical manifestations in a multiethnic case series. Our findings differed slightly from the previous data in other populations.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/4439
Referências
  1. Arnett F C, 1995, Int Rev Immunol, V12, P107, DOI 10.3109/08830189509056707
  2. Arnett FC, 1996, ARTHRITIS RHEUM, V39, P1151, DOI 10.1002/art.1780390712
  3. Arnett FC, 2010, ANN RHEUM DIS, V69, P822, DOI 10.1136/ard.2009.111906
  4. Beretta L, 2012, RHEUMATOLOGY, V51, P52, DOI 10.1093/rheumatology/ker335
  5. Bernatsky S, 2009, ARTHRIT RHEUM-ARTHR, V61, P400, DOI 10.1002/art.24339
  6. BRIGGS D, 1993, ARTHRITIS RHEUM, V36, P943, DOI 10.1002/art.1780360711
  7. Chifflot H, 2008, SEMIN ARTHRITIS RHEU, V37, P223, DOI 10.1016/j.semarthrit.2007.05.003
  8. Fanning GC, 1998, BRIT J RHEUMATOL, V37, P201
  9. Frezza D, 2007, ANN RHEUM DIS, V66, P1210, DOI 10.1136/ard.2006.066597
  10. Gilchrist FC, 2001, GENES IMMUN, V2, P76, DOI 10.1038/sj.gene.6363734
  11. Gladman DD, 2005, J RHEUMATOL, V32, P1481
  12. HARRISON NK, 1991, AM REV RESPIR DIS, V144, P706
  13. Karp D. R., 2009, HUM MOL GENET, V19, P707
  14. KUWANA M, 1995, ANN RHEUM DIS, V54, P983, DOI 10.1136/ard.54.12.983
  15. KUWANA M, 1993, J CLIN INVEST, V92, P1296, DOI 10.1172/JCI116703
  16. Lambert NC, 2000, ARTHRITIS RHEUM, V43, P2005, DOI 10.1002/1529-0131(200009)43:9<2005::AID-ANR11>3.0.CO;2-#
  17. LANGEVITZ P, 1992, BRIT J RHEUMATOL, V31, P609
  18. Lenna S, 2010, J IMMUNOL, V184, P4654, DOI 10.4049/jimmunol.0903188
  19. LEROY EC, 1988, J RHEUMATOL, V15, P202
  20. Loubiere LS, 2005, RHEUMATOLOGY, V44, P318, DOI 10.1093/rheumatology/keh489
  21. MARGUERIE C, 1992, MEDICINE, V71, P327, DOI 10.1097/00005792-199211000-00001
  22. MOREL PA, 1994, HUM IMMUNOL, V40, P101, DOI 10.1016/0198-8859(94)90054-X
  23. Poormoghim H, 2000, ARTHRITIS RHEUM, V43, P444, DOI 10.1002/1529-0131(200002)43:2<444::AID-ANR27>3.0.CO;2-G
  24. Radstake TRDJ, 2010, NAT GENET, V42, P426, DOI 10.1038/ng.565
  25. Ramirez Allan, 2004, Treat Respir Med, V3, P339, DOI 10.2165/00151829-200403060-00002
  26. REVEILLE JD, 1992, J CLIN INVEST, V89, P1208, DOI 10.1172/JCI115704
  27. Reveille JD, 2001, SEMIN ARTHRITIS RHEU, V30, P332, DOI 10.1053/sarh.2001.20268
  28. REVEILLE JD, 1992, J CLIN INVEST, V90, P973, DOI 10.1172/JCI115974
  29. Santaniello A, 2006, TISSUE ANTIGENS, V68, P239, DOI 10.1111/j.1399-0039.2006.00657.x
  30. Simeon CP, 2009, J RHEUMATOL, V36, P2733, DOI [10.3899/jrheum.090377, 10.3899/jrheum090377]
  31. Steen VD, 2007, ANN RHEUM DIS, V66, P940, DOI 10.1136/ard.2006.066068
  32. Tan FK, 1999, TISSUE ANTIGENS, V53, P74, DOI 10.1034/j.1399-0039.1999.530108.x
  33. WHYTE J, 1994, J AUTOIMMUN, V7, P509, DOI 10.1006/jaut.1994.1037
  34. Zhou XD, 2009, ARTHRITIS RHEUM, V60, P3807, DOI 10.1002/art.24982

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/17
Artigos e Materiais de Revistas Científicas - ODS/03